Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bamberg, Germany
-
Berg, Germany
-
Berlin, Germany
-
Bremen, Germany
-
Dortmund, Germany
-
Dresden, Germany
-
Duisburg, Germany
-
Erlangen, Germany
-
Eschweiler, Germany
-
Frankfurt / Main, Germany
-
Freiburg, Germany
-
Goch, Germany
-
Greifswald, Germany
-
Göttingen, Germany
-
Halle, Germany
-
Hamburg, Germany
-
Hamm, Germany
-
Jena, Germany
-
Karlsruhe, Germany
-
Kempten, Germany
-
Kiel, Germany
-
Kÿln N/A, Germany
-
Lübeck, Germany
-
Magdeburg, Germany
-
Mutlangen, Germany
-
München, Germany
-
Münster, Germany
-
Nürnberg, Germany
-
Oldenburg, Germany
-
Regensburg, Germany
-
Rostock, Germany
-
Stuttgart, Germany
-
Trier, Germany
-
Ulm, Germany
-
Villingen-Schwenningen, Germany
-
Wiesbaden, Germany
-
Würzburg, Germany
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who have had pretreatment with single or tandem high dose melphalan therapy and autologous stem cell transplantation as first line therapy
- at least stable disease after stem cell transplantation
- adequate hematological, hepatic and renal lab parameters
- karnofsky status of 70 or more
Exclusion Criteria:
- non-secretory multiple myeloma
- previous treatment with bortezomib
- allogenic stem cell transplantation
- other co-existing malignancy beside basaliome
- peripheral neuropathy
- epilepsia
- other severe comorbidities (renal, hepatic, cardiovascular, metabolic, infectious etc.)
- history of allergic reactions to bortezomib or mannitol
- expected life expectancy of less than 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bortezomib
Bortezomib 1.6 mg/m2 i.v.
d1 d8 d15 d22 for 4 cycles each of 35 days
|
1.6 mg/m2 i.v.
d1 d8 d15 d22 for 4 cycles each of 35 days
|
|
No Intervention: Observation
Observational arm
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The difference in event-free survival time will be compared between both arms
Time Frame: Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up
|
Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Best response to chemotherapy, response rate to chemotherapy , duration of response, toxicities and quality of life; timepoints for assessments will be at end of study, at 1,5 + 4 + 8 +12 + 18 + 24 + 30 months and thereafter 6 monthly
Time Frame: Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up
|
Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Straka C, Knop S, Vogel M, Muller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Durk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rosler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. Eur J Haematol. 2019 Sep;103(3):255-267. doi: 10.1111/ejh.13281. Epub 2019 Jul 19.
- Einsele H, Knop S, Vogel M, Muller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Durk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rosler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia. 2017 Jun;31(6):1463-1466. doi: 10.1038/leu.2017.83. Epub 2017 Mar 15. No abstract available.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Bortezomib
Other Study ID Numbers
Other Study ID Numbers
- CR006127
- 26866138MMY3013 (Other Identifier: Janssen-Cilag G.m.b.H, Germany)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.